Research News

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

CDF has been approved for a $100,000 funding award through the Eugene Washington PCORI Engagement Awards program. The funds will support the community convening of patient advocates, researchers, and other key stakeholders to create a roadmap for patient advocate engagement in research.

People with celiac disease have a 10-fold greater risk for inflammatory bowel disease (IBD). Those with IBD have a 4-fold greater risk for celiac disease. A new study reviews the link between these two autoimmune disorders.

TAK-062, an orally administered synthetic enzyme that survives the acidity of the stomach and digests gluten effectively, has passed its phase 1 clinical drug trial, indicating it is safe to use in celiac patients.

Showcasing the “brightest ideas and breakthroughs in digestive disease,” DDW 2020 includes recent studies and innovations in celiac disease and gluten-related disorders, some of which we have curated and summarized for you.